← Back to headlines
Merck Acquires Cancer Biotech Terns in Nearly $6 Billion Deal
Pharmaceutical giant Merck has reached an agreement to acquire cancer biotech company Terns in a deal valued at nearly $6 billion, expanding its portfolio in oncology.
25 Mar, 13:14 — 25 Mar, 13:14
Sources
Showing 1 of 1 sources
